课题基金 / 基金详情

CYSTEAMINE BITARTRATE DELAYED-RELESEASE CAPSULES (RP103) COMPARED TO CYSTEAMINE

CYSTEAMINE BITARTRATE DELAYED-RELESEASE CAPSULES (RP103) COMPARED TO CYSTEAMINE
半胱胺酒石酸氢盐延迟释放胶囊 (RP103) 与半胱胺相比
批准号：
8166878
负责人：
BRUCE A BARSHOP
金额：
$1.95万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-12-01 至 2010-06-30
来源：
https://reporter.nih.gov/project-details/8166878
关键词：
AssesComputer Retrieval of Information on Scientific Projects DatabaseCystagonCysteamineCystinosisEnrollmentFundingGrantInstitutionPatientsResearchResearch PersonnelResourcesSafetySourceUnited States National Institutes of Healthcapsuledesign

项目摘要

项目成果

BRUCE A BARSHOP的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 评估RP 103与胱抑素相比在肾病性胱氨酸病患者中的PK、PD、安全性和耐受性。 服用Cystagon作为胱氨酸病治疗的一部分的患者将入组研究，结果将用于设计比较RP 103与Cystagon的确证性PK和关键PD研究。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asses the PK, PD, safety and tolerability of RP103 compared to Cystagon in patients with nephropathic cystinosis. Patients taking Cystagon as part of their treatment for cystinosis will be enrolled into the study and results will be used to inform the design the confirmatory PK and pivotal PD study comparing RP103 to Cystagon.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR
CLINICAL TRIAL: ALGLUCOSIDASE ALFA TEMPORARY ACCESS PROGRAM (ATAP) PROTOCOL AGLU
CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR
CLINICAL TRIAL: MYOZYME? TEMPORARY ACCESS PROGRAM (MTAP)